New Method for Viewing Root Surfaces

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/142213/1/jper0673.pd

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

Correction to: Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

The original version of this article unfortunately contained a mistake

Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis

Trypanosoma brucei relies on an essential Variant Surface Glycoprotein (VSG) coat for survival in the mammalian bloodstream. High VSG expression within an expression site body (ESB) is mediated by RNA polymerase I (Pol I), which in other eukaryotes exclusively transcribes ribosomal RNA genes (rDNA). As T. brucei is reliant on Pol I for VSG transcription, we investigated Pol I transcription inhibitors for selective anti-trypanosomal activity. The Pol I inhibitors quarfloxin (CX-3543), CX-5461, and BMH-21 are currently under investigation for treating cancer, as rapidly dividing cancer cells are particularly dependent on high levels of Pol I transcription compared with nontransformed cells. In T. brucei all three Pol I inhibitors have IC50 concentrations for cell proliferation in the nanomolar range: quarfloxin (155 nM), CX-5461 (279 nM) or BMH-21 (134 nM) compared with IC50 concentrations in the MCF10A human breast epithelial cell line (4.44 μM, 6.89 μM or 460 nM, respectively). T. brucei was therefore 29-fold more sensitive to quarfloxin, 25-fold more sensitive to CX-5461 and 3.4-fold more sensitive to BMH-21. Cell death in T. brucei was due to rapid inhibition of Pol I transcription, as within 15 minutes treatment with the inhibitors rRNA precursor transcript was reduced 97-98% and VSG precursor transcript 91-94%. Incubation with Pol I transcription inhibitors also resulted in disintegration of the ESB as well as the nucleolus subnuclear structures, within one hour. Rapid ESB loss following the block in Pol I transcription argues that the ESB is a Pol I transcription nucleated structure, similar to the nucleolus. In addition to providing insight into Pol I transcription and ES control, Pol I transcription inhibitors potentially also provide new approaches to treat trypanosomiasi

Periodontics - historical

Pernsteiner, Clair, "Dental Assistant's Role in Periodontal Surgery": The Periodontal Surgery set-up, using four-handed dentistry and a chairside assistant. (20:28) Orig. air date: FEB 17 72Baity, [], "Survey of Scaler Design": Demonstrates the design of various curets, sickles, files and hoes. (9:30) Orig. air date: DEC 1 72Baity, [], "Periodontal Charting Procedure": This tape reviews the charting procedures used in Periodontal clinic examinations. This is long version of 204-3. (27:12) Orig. air date: MAR 16 72Shick, Richard, "Periodontal Surgery (Muco-Periosteal Flap)": Utilization of inverse bevel incision to perform periodontal surgery. Also shows suturing, placement of dressing and dismissal of patient. (63:00) Orig. air date: JAN 4 72Baity, [], "Instrument Sharpening": How to sharpen periodontal instruments. (14:35) Orig. air date: DEC 9 71Baity, [], "Ultrasonic Scaling": Indications and contra-indications for ultrasonic scaling. (14:48) Orig. air date: JAN 13 72Ramfjord, Sigurd P.; Gilson, Mark, "Oral Hygiene Methods - Toothbrushing and Flossing": This tape is a compilation of three 16mm films which demonstrate the circular scrubb and Bass methods of toothbrushing and good technique in dental flossing. (16:15) Orig. air date: NOV 16 72Baity, [], "Introduction to Oral Health: Clinic Session I": The identification of the various gingival landmarks in the mouth and a plaque control score procedure is demonstrated. (20:16) Orig. air date: OCT 31 73Appleberry, Eric, "Laboratory Exercise: Root Planing & Polishing": This tape demonstrates the root scaling, plaining and porte polishing of extracted teeth. (25:00) Orig. air date: MAR 21 77Ramfjord, Sigurd P.; Green, Edward, "Periodontal Examination Part I: Examination Procedures": Shows the procedure for a thorough periodontic examination. (16:00) Orig. air date: May 27 80Ramfjord, Sigurd P.; Green, Edward, "Periodontal Examination Part II: Charting": Tape demonstrates the use of the periodontic chart, and shows the actual charting of the teeth in the mouth. (18:00) Orig. air date: May 27 80Ramfjord, Sigurd P.; Green, Edward, "Scaling and Root Planing: Part II Mandibular Teeth": Procedures for scaling and root planing the mandibular teeth. (10:34) Orig. air date: May 27 80Ramfjord, Sigurd P., "Immediate Custom Implant for the Mandible": (13:00) Orig. air date: May 27 80Ramfjord, Sigurd P., "Toothbrushing Part II": Film Transfer Orig. air date: May 27 80Baity, [], "Dental Anatomy and Periodontics": Basic relationships between tooth morphology and periodontal procedures and instrumentation. Introduction to the clinical area of Periodontics. (39:03) Orig. air date: JUN 12 74Ramfjord, Sigurd P.; Kerry, Gloria J., "Lateral Sliding Flap": Surgical procedure performed on Maxillary Central Incisor to cover an exposed root with gum tissue. (14:00) Orig. air date: MAY 2 73Ramfjord, Sigurd P.; Green, Edward, "Modified Widman Flap (revised)": Orig. air date: May 27 80Ramfjord, Sigurd P.; Karring, Torkild, "Gingival and Bone Grafting for New Attachment": (15:34) Orig. air date: May 27 80Ramfjord, Sigurd P.; Green, Edward, "Initial or Hygiene Phase of Periodontal Therapy": Procedures to be included in the initial or Hygient phase of Periodontal therapy. (17:10) Orig. air date: May 27 80Ramfjord, Sigurd P., "Reverse Bevel Flap": Shows the periodontal surgery on maxillary anterior teeth, using reverse bevel flap procedure. (19:00) Orig. air date: May 27 80Ramfjord, Sigurd P.; Knowles, James W., "Sliding Flap with Free Gingival Graft": (15:34) Orig. air date: May 27 80Ramfjord, Sigurd P.; Green, Edward, "Subgingival Curettage": Shows several methods ofSubgingival Curettage on patients with Periodontal Pockets. (15:00) Orig. air date: May 27 80http://deepblue.lib.umich.edu/bitstream/2027.42/64971/2/131-2PerioDentalAssit.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/3/133-1ScalerDesign.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/4/137-1PerioChart.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/5/150MucoPeriostealFlap.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/6/154-1InstrumentSharpening.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/7/154-3UltrasonicScaling.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/8/192-3.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/9/329-1Intro2OH.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/10/391-1RootPlaining.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/11/733-1.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/12/734-1.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/13/734-2.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/14/895-1.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/15/896-1.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/16/AnatPerio_385-1.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/17/LatSlidingFlap_735-2.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/18/ModifiedWindman_737-2.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/19/NewAttach_746-1.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/20/PerioSurgeryInit_736-1.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/21/ReverseBevel_688-1.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/22/SlidingFlap_745.movhttp://deepblue.lib.umich.edu/bitstream/2027.42/64971/23/SubgingivCurret_737-1.mo